HK1197264A1 - Ion concentration-dependent binding molecule library - Google Patents

Ion concentration-dependent binding molecule library

Info

Publication number
HK1197264A1
HK1197264A1 HK14110511A HK14110511A HK1197264A1 HK 1197264 A1 HK1197264 A1 HK 1197264A1 HK 14110511 A HK14110511 A HK 14110511A HK 14110511 A HK14110511 A HK 14110511A HK 1197264 A1 HK1197264 A1 HK 1197264A1
Authority
HK
Hong Kong
Prior art keywords
binding molecule
ion concentration
dependent binding
molecule library
library
Prior art date
Application number
HK14110511A
Other languages
English (en)
Chinese (zh)
Inventor
井川智之
石井慎也
舩木美步
廣庭奈緒香
清水駿
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1197264A1 publication Critical patent/HK1197264A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK14110511A 2011-09-30 2014-10-21 Ion concentration-dependent binding molecule library HK1197264A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011218006 2011-09-30
JP2012123479 2012-05-30
PCT/JP2012/006254 WO2013046722A1 (fr) 2011-09-30 2012-09-28 Bibliothèque de molécules de liaison dépendant de la concentration ionique

Publications (1)

Publication Number Publication Date
HK1197264A1 true HK1197264A1 (en) 2015-01-09

Family

ID=47994796

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18103922.7A HK1244517A1 (zh) 2011-09-30 2014-10-21 離子濃度依賴性結合分子文庫
HK14110511A HK1197264A1 (en) 2011-09-30 2014-10-21 Ion concentration-dependent binding molecule library

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18103922.7A HK1244517A1 (zh) 2011-09-30 2014-10-21 離子濃度依賴性結合分子文庫

Country Status (15)

Country Link
US (3) US10024867B2 (fr)
EP (2) EP2762564B1 (fr)
JP (4) JP6284766B2 (fr)
KR (2) KR102528622B1 (fr)
CN (3) CN113061993A (fr)
AU (2) AU2012313594C1 (fr)
BR (2) BR122019023952B1 (fr)
CA (2) CA3186007A1 (fr)
HK (2) HK1244517A1 (fr)
IN (1) IN2014CN03066A (fr)
MX (2) MX366269B (fr)
RU (1) RU2732151C2 (fr)
SG (2) SG10202102283TA (fr)
TW (3) TWI710675B (fr)
WO (1) WO2013046722A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2006381B1 (fr) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Procédé de régulation de la pharmacocinétique sanguine des anticorps
EP4368721A2 (fr) 2007-09-26 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Procédé de modification du point isoélectrique d'un anticorps par substitution d'acide aminé dans cdr
NO2708559T3 (fr) 2008-04-11 2018-08-25
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
KR20200103845A (ko) 2011-02-25 2020-09-02 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
TW201817744A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
TWI681970B (zh) 2011-09-30 2020-01-11 日商中外製藥股份有限公司 包含依離子濃度之條件對抗原之結合活性會改變之抗原結合分域、及於pH中性之條件下對FcRn有結合活性之FcRn結合分域、且誘導對標的抗原的免疫反應之抗原結合分子
EP3939996A1 (fr) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
CN104080909A (zh) 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
MX2014011047A (es) 2012-03-16 2015-04-08 Regeneron Pharma Ratones que producen proteinas de union a un antigeno con caracteristicas de union dependientes del ph.
NZ629639A (en) 2012-03-16 2017-03-31 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
KR102345232B1 (ko) 2012-03-16 2021-12-30 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
JP6470170B2 (ja) * 2012-04-27 2019-02-13 バイオアトラ、エルエルシー 改変抗体領域およびその使用
WO2013180200A1 (fr) 2012-05-30 2013-12-05 中外製薬株式会社 Molécule de liaison d'antigène spécifique à un tissu cible
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
KR102273985B1 (ko) 2012-08-24 2021-07-06 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ영역 개변체
KR102318483B1 (ko) 2013-04-02 2021-10-27 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
HUE044747T2 (hu) * 2013-09-18 2019-11-28 Regeneron Pharma Hisztidinmódosított könnyûláncú antitestek és genetikailag módosított nem humán állati élõlények ugyanennek az elõállítására
DK3078744T3 (da) 2013-12-04 2020-09-28 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyler, antigen-bindingsaktiviteten af hvilke varierer i henhold til koncentrationen af forbindelser, og biblioteker af molekylerne
CA2947605A1 (fr) * 2014-05-13 2015-11-19 Bioatla, Llc Proteines biologiques conditionnellement actives
JP7037885B2 (ja) 2014-06-30 2022-03-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ｐＨ依存性抗原結合を示す抗ＴＮＦａ抗体
JP6858559B2 (ja) * 2014-08-20 2021-04-14 中外製薬株式会社 蛋白質溶液の粘度測定方法
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
AU2015308818B2 (en) 2014-08-28 2021-02-25 Bioatla Llc Conditionally active chimeric antigen receptors for modified T-cells
US10870704B2 (en) * 2014-10-23 2020-12-22 Kira Biotech Pty Limited CD83 binding proteins and uses thereof
CA2963760A1 (fr) 2014-12-19 2016-06-23 Yoshinao Ruike Anticorps anti-myostatine, polypeptides contenant des variants de regions fc, et procedes d'utilisation
JP2018511557A (ja) 2015-01-22 2018-04-26 中外製薬株式会社 ２種以上の抗ｃ５抗体の組み合わせおよび使用方法
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
CN107580603A (zh) * 2015-02-24 2018-01-12 生物蛋白有限公司 条件活性生物蛋白
EP3549606A1 (fr) 2015-05-28 2019-10-09 Bio-rad Laboratories, Inc. Ligands d'affinité et procédés associés
CR20180217A (es) 2015-09-18 2018-05-03 Chugai Pharmaceutical Co Ltd Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
EP3371349A4 (fr) 2015-11-02 2018-09-12 Bioatla, LLC Polypeptides conditionnellement actifs
WO2017110981A1 (fr) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine et procédés d'utilisation
EP3455261B1 (fr) 2016-05-13 2022-08-03 BioAtla, Inc. Anticorps anti-ror2, fragments d'anticorps, leurs immunoconjugués et utilisations correspondantes
CA3026050A1 (fr) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition pour la prophylaxie ou le traitement de maladies liees a il-8
GB201615254D0 (en) 2016-09-08 2016-11-23 Ge Healthcare Bio Sciences Ab Novel Ligand and use thereof
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3579866A4 (fr) * 2017-02-08 2020-12-09 Dragonfly Therapeutics, Inc. Domaines variables de chaînes lourdes d'anticorps ciblant le récepteur nkg2d
CA3221995C (fr) 2017-02-08 2024-05-28 Dragonfly Therapeutics, Inc. Proteines de fixation multi-specifiques destinees a l'activation de cellules tueuses naturelles et leurs utilisations therapeutiques pour traiter le cancer
KR20240060739A (ko) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
EP3609915A1 (fr) * 2017-04-12 2020-02-19 Pfizer Inc Anticorps ayant une affinité conditionnelle et leurs procédés d'utilisation
MX2019014576A (es) * 2017-06-05 2020-07-29 Janssen Biotech Inc Anticuerpos multiespecíficos manipulados genéticamente y otras proteínas multiméricas con mutaciones asimétricas en la región ch2-ch3.
WO2019064463A1 (fr) * 2017-09-28 2019-04-04 学校法人中部大学 Procédé et dispositif pour la concentration de virus ou de bactérie par bioaffinité
JP2021502967A (ja) 2017-11-14 2021-02-04 中外製薬株式会社 抗Ｃ１ｓ抗体および使用方法
MX2020008336A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
WO2019177543A1 (fr) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anticorps dirigés contre le virus de la dengue présentant une réactivité croisée au virus zika et procédés d'utilisation
KR102115300B1 (ko) 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
US11396542B2 (en) 2018-08-21 2022-07-26 Synkrino Biotherapeutics, Inc. Astrotactin1-based compositions and pharmaceutical formulations
US20210246220A1 (en) * 2018-10-10 2021-08-12 Bgi Shenzhen Anti-BCMA single-chain antibody scFv and preparation method and application thereof
WO2020186111A2 (fr) * 2019-03-12 2020-09-17 xCella Biosciences, Inc. Anticorps se liant à vista et leurs utilisations
JP2022525261A (ja) * 2019-03-12 2022-05-11 ザイエンス・セラピューティクス・インコーポレイテッド ビスタ結合抗体およびその使用
WO2021087368A2 (fr) * 2019-11-01 2021-05-06 Magenta Therapeutics, Inc. Anticorps anti-cd45 et leurs conjugués
CR20220277A (es) 2019-12-18 2022-08-31 Hoffmann La Roche Anticuerpos anti-ccl2 biespecifico
CN112086160B (zh) * 2020-08-26 2023-09-22 江西中医药大学 基于Softmax和混合粒子群的中药量效拟合方法
WO2022263501A1 (fr) 2021-06-18 2022-12-22 F. Hoffmann-La Roche Ag Anticorps anti-ccl2 bispécifiques

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0266032A1 (fr) 1986-08-29 1988-05-04 Beecham Group Plc Enzyme fibrinolytique modifiée
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH0636741B2 (ja) * 1989-11-08 1994-05-18 帝人株式会社 ヒト・プロテインｃの分離方法
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2089661C (fr) 1990-08-29 2007-04-03 Nils Lonberg Animaux transgeniques non humains capables de produire des anticorps heterologues
ES2130177T3 (es) 1991-08-10 1999-07-01 Medical Res Council Tratamiento de poblaciones de celulas.
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
WO1993011236A1 (fr) 1991-12-02 1993-06-10 Medical Research Council Production d'anticorps anti-auto-antigenes a partir de repertoires de segments d'anticorps affiches sur phage
CA2124967C (fr) 1991-12-17 2008-04-08 Nils Lonberg Animaux transgeniques non humains capables de produire des anticorps heterologues
EP0656941B1 (fr) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Procedes de production d'elements de paires de liaison specifiques
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
US6214613B1 (en) * 1993-12-03 2001-04-10 Ashai Kasei Kogyo Kabushiki Kaisha Expression screening vector
EP0731842A1 (fr) 1993-12-03 1996-09-18 Medical Research Council Proteines et peptides de liaison recombines
US5994524A (en) 1994-07-13 1999-11-30 Chugai Seiyaku Kabushiki Kaisha Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same
CA2761116A1 (fr) 1995-04-27 1996-10-31 Amgen Fremont Inc. Anticorps humains derives d'une xenosouris immunisee
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
IL140918A0 (en) 1998-07-27 2002-02-10 Genentech Inc Improved transformation efficiency in phage display through modification of a coat protein
DK1332209T3 (da) 2000-09-08 2010-03-29 Univ Zuerich Samlinger af repeatproteiner indeholdende repeatmoduler
JP2004526419A (ja) 2000-10-16 2004-09-02 フィロス インク． 抗体模倣物および他の結合タンパク質のためのタンパク質骨格
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
WO2003029462A1 (fr) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteines de la lipocaline neutrophile humaine associee a la gelatinase et de proteines apparentees
DE10207178A1 (de) * 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
WO2003105757A2 (fr) * 2002-06-12 2003-12-24 Genencor International, Inc. Methodes et compositions de liaison dependant du milieu d'un agent cible a une cible
AU2004284090A1 (en) 2003-10-24 2005-05-06 Avidia, Inc. LDL receptor class A and EGF domain monomers and multimers
SG10202008722QA (en) 2003-11-05 2020-10-29 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
EP1871808A2 (fr) 2005-03-31 2008-01-02 Xencor, Inc. VARIANTS Fc PRESENTANT DES PROPRIETES OPTIMISEES
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
CA2659574C (fr) 2006-08-02 2017-04-25 The Uab Research Foundation Procedes et compositions apparentes a des recepteurs de lymphocytes variables monoclonaux solubles d'une specificite antigenique definie
WO2008092117A2 (fr) 2007-01-25 2008-07-31 Xencor, Inc. Nouvelles insertions, délétions et substitutions d'immunoglobulines
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
MX2010003158A (es) 2007-09-28 2010-04-14 Chugai Pharmaceutical Co Ltd Anticuerpo anti-glipicano-3 que tiene cinetica mejorada en plasma.
AU2008343591A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Engineered hybird phage vectors for the design and the generation of a human non-antibody peptide or protein phage library via fusion to pIX of M13 phage
EP2235059B1 (fr) 2007-12-26 2015-02-18 Xencor, Inc. Variants de fc avec une liaison altérée à fcrn
NO2708559T3 (fr) 2008-04-11 2018-08-25
EP3670538A1 (fr) * 2008-04-25 2020-06-24 Dyax Corp. Anticorps contre fcrn et leur utilisation
WO2009139822A1 (fr) 2008-05-01 2009-11-19 Amgen Inc. Anticorps anti-hepcidine et méthodes d’utilisation associées
WO2010058860A1 (fr) * 2008-11-18 2010-05-27 株式会社シノテスト Procédé de mesure et réactif de mesure pour la protéine c-réactive dans un échantillon
WO2010136598A1 (fr) 2009-05-29 2010-12-02 Morphosys Ag Collection et ses procédés d'utilisation
KR20120138241A (ko) * 2010-03-11 2012-12-24 화이자 인코포레이티드 ｐＨ 의존성 항원 결합을 갖는 항체
JP2011184418A (ja) * 2010-03-11 2011-09-22 Tokyo Institute Of Technology 親和性可変抗体
AU2011337704B2 (en) * 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly

Also Published As

Publication number Publication date
US20220187308A1 (en) 2022-06-16
RU2014117636A (ru) 2015-11-10
BR122019023952B1 (pt) 2022-09-20
JP6284766B2 (ja) 2018-02-28
US20190041396A1 (en) 2019-02-07
KR20210091341A (ko) 2021-07-21
KR20140069074A (ko) 2014-06-09
EP2762564B1 (fr) 2020-09-16
CA2850041C (fr) 2023-03-14
SG10202102283TA (en) 2021-04-29
EP3778889A1 (fr) 2021-02-17
AU2018201987A1 (en) 2018-04-12
CA3186007A1 (fr) 2013-04-04
BR112014007353A2 (pt) 2017-04-04
CN103975060B (zh) 2021-04-13
IN2014CN03066A (fr) 2015-08-07
EP2762564A1 (fr) 2014-08-06
EP2762564A4 (fr) 2015-04-29
JP7012044B2 (ja) 2022-02-10
JP6523387B2 (ja) 2019-05-29
MX2014003662A (es) 2014-04-30
US10024867B2 (en) 2018-07-17
TWI794658B (zh) 2023-03-01
US20140271617A1 (en) 2014-09-18
JPWO2013046722A1 (ja) 2015-03-26
WO2013046722A1 (fr) 2013-04-04
AU2012313594C1 (en) 2018-05-10
MX2019007958A (es) 2019-08-29
TW202106936A (zh) 2021-02-16
TW201738417A (zh) 2017-11-01
MX366269B (es) 2019-07-04
KR102276528B1 (ko) 2021-07-12
CA2850041A1 (fr) 2013-04-04
AU2012313594A1 (en) 2014-04-17
AU2018201987B2 (en) 2020-10-01
JP2022028652A (ja) 2022-02-16
AU2012313594B2 (en) 2018-02-01
TWI710675B (zh) 2020-11-21
CN103975060A (zh) 2014-08-06
TW201329299A (zh) 2013-07-16
JP2018070589A (ja) 2018-05-10
SG11201401102VA (en) 2014-09-26
US11243210B2 (en) 2022-02-08
CN107287660A (zh) 2017-10-24
RU2732151C2 (ru) 2020-09-11
KR102528622B1 (ko) 2023-05-04
BR112014007353B1 (pt) 2022-09-13
JP2019193629A (ja) 2019-11-07
JP7313410B2 (ja) 2023-07-24
CN113061993A (zh) 2021-07-02
HK1244517A1 (zh) 2018-08-10

Similar Documents

Publication Publication Date Title
HK1197264A1 (en) Ion concentration-dependent binding molecule library
IL270223B (en) Molecules that specifically bind tdp–43
HK1198630A1 (en) Protein carrier-linked prodrugs
HK1214938A1 (zh) 分析輔件
GB201104542D0 (en) Content provision
EP2685487A4 (fr) Spectromètre de masse
AU341416S (en) Dehumidifier housing
GB2493276B (en) RF ion guides
EP2754036A4 (fr) Bibliothèque d'animations à base de scénarios
PL3617697T3 (pl) Zsynchronizowana modyfikacja jonów
EP2766917A4 (fr) Spectrometre de masse
IL235134A0 (en) il–6 binding molecules
GB201117158D0 (en) Ion guide
EP2720722A4 (fr) Molécule contenant de multiples groupes vinylsulfone
EP2739764A4 (fr) Source d'ions
EP2793918A4 (fr) Peptides de liaison à hdc-sign
EP2671947A4 (fr) Banque de peptides
EP2732447A4 (fr) Échantillon audio
EP2793021A4 (fr) Adsorbant de protéine
IL227971A0 (en) Substances that inhibit the transport of glycine
GB201200563D0 (en) Binding molecule
GB201116477D0 (en) Modified boot
GB201113890D0 (en) Binding surfaces
GB201110613D0 (en) Comb binding
GB201121148D0 (en) Rotating binding for snowboard